Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • Barinthus Biotherapeutics' Total Current Liabilities fell 2835.72% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 2835.72%. This contributed to the annual value of $15.7 million for FY2024, which is 2428.16% up from last year.
  • Barinthus Biotherapeutics' Total Current Liabilities amounted to $10.8 million in Q3 2025, which was down 2835.72% from $12.7 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Total Current Liabilities registered a high of $18.6 million during Q3 2023, and its lowest value of $6.4 million during Q3 2021.
  • In the last 5 years, Barinthus Biotherapeutics' Total Current Liabilities had a median value of $12.2 million in 2022 and averaged $12.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 12019.77% in 2022, then tumbled by 2835.72% in 2025.
  • Barinthus Biotherapeutics' Total Current Liabilities (Quarter) stood at $11.2 million in 2021, then increased by 9.72% to $12.2 million in 2022, then increased by 2.91% to $12.6 million in 2023, then rose by 24.28% to $15.7 million in 2024, then tumbled by 31.03% to $10.8 million in 2025.
  • Its Total Current Liabilities stands at $10.8 million for Q3 2025, versus $12.7 million for Q2 2025 and $12.0 million for Q1 2025.